Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies, presented new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Boston, showing that its next-generation suppressor tRNAs (sup-tRNAs) restore full-length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). The company also reported durable rescue of full-length titin protein in a mouse model and functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM-TTNtv).
The data, presented from May 11-15, demonstrate that Tevard's suppressor tRNA platform can achieve approximately 100% restoration of full-length dystrophin in DMD models, a significant advancement for patients with nonsense mutations that cause premature stop codons. For DCM-TTNtv, the therapy provided durable rescue of full-length titin, a protein essential for heart muscle function. The company highlighted that its compact tRNA architecture enables flexible AAV packaging, precise dose control, and broad applicability for pathogenic nonsense mutations across diverse unmet medical needs.
These results underscore the versatility of the suppressor tRNA platform and its ability to restore native protein expression in a cell-specific, durable manner. Tevard is advancing programs in muscular dystrophies, heart disease, and neurological disorders, and the presented data support the potential of this approach to address a wide range of genetic diseases caused by premature termination codons. For more information, visit www.tevard.com.
